

SmartPA Criteria Proposal

Drug/Drug Class:	Benzoyl Peroxide/Antibiotic Combinations PDL Edit
First Implementation Date:	July 1, 2010
Proposed Date:	March 17, 2022
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Acne vulgaris, commonly called acne, is a skin disease caused by changes in the pilosebaceous units. Severe acne is inflammatory in nature but can also manifest in non-inflammatory forms. Acne lesions are commonly referred to as pimples, spots, or zits. This self-limiting disorder affects primarily teenagers and young adults. In adolescence, sebaceous glands increase sebum release after puberty. Small cysts called comedones form in hair follicles as a result of blockage of the pore causing retention of sebum and keratinous material. Bacterial activity, most often due to *Propionibacterium acnes*, within the comedones releases free fatty acids from sebum, causing inflammation within the cyst. Elimination of the comedones, generally achieved by decreasing sebaceous gland activity, bacterial population, and inflammation, is the goal of treatment.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> Clindamycin/Benzoyl Peroxide 1.2%/5% (gen Duac®) 	<ul style="list-style-type: none"> Acanya® BenzaClin® Benzamycin® Clindamycin/Benzoyl Peroxide 1.2%/2.5% (gen Acanya®) Clindamycin/Benzoyl Peroxide 1%/5% (gen BenzaClin®) Erythromycin/Benzoyl Peroxide (gen Benzamycin®) Neuac® Onexton®

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Benzoyl Peroxide/Antibiotic Combinations
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 1 preferred agent
 - Documented trial period of preferred agents
 - Documented ADE/ADR to preferred agents

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:

MedWatch Form:

Progress Notes:

Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

- Evidence-Based Medicine and Fiscal Analysis: "Topical Antibiotic/Benzoyl Peroxide Agents - Topical Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; January 2022.
- Evidence-Based Medicine Analysis: "Benzoyl Peroxide/Clindamycin Topical Agents", UMKC-DIC; February 2022.
- USPDI, Micromedex; 2022.
- Facts and Comparisons eAnswers (online); 2022 Clinical Drug Information, LLC.